URGN Company Profile and Key Details

Q: Who are the executives of URGN?

Mr. Jason Drew SmithGen. Counsel, Chief Compliance Officer & Corporation Sec.Dr. Marina KonortyExecutive Vice President of R&D and Technical OperationsMs. Elizabeth A. BarrettPres, Chief Executive Officer & DirectorMr. James Ottinger R.ph.Executive Vice President of Regulatory Affairs & QualityMr. Dong KimChief Financial OfficerEric Van ZantenSenior Director of CommunicationsDr. Sari Prutchi-Sagiv Ph.D.Marketing DirectorMr. Jeffrey Bova M.B.A.Chief Commercial OfficerDr. Mark P. Schoenberg M.D.Chief Medical OfficerVincent I. PerroneSenior Director of Investor RelationsMr. Eric Van ZantenVice President of Investor & PR

NASDAQ : URGN

UroGen Pharma

$23.29

0.29+1.26%

At Close 4:00 PM

60.56

BESG ScoreESG Rating

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Price Chart

Stock Price Today

UroGen Pharma Ltd. (URGN) stock surged +1.26%, trading at $23.29 on NASDAQ, up from the previous close of $23.00. The stock opened at $23.20, fluctuating between $22.69 and $23.64 in the recent session.

Stock Snapshot

Prev. Close

1.13B

Market Cap

22.69

Day Low

-7.3

P/E Ratio

-3.19

EPS (TTM)

-2.12

Cash Flow per Share

23.2

Open

48.68M

Number of Shares

23.64

Day High

80.04%

Free Float in %

-1.8

Book Value

617.48K

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
May 04, 2026	23.20	23.67	22.68	23.29	624.19K
Apr 30, 2026	23.57	23.98	23.11	23.83	389.43K
Apr 29, 2026	24.01	24.28	23.17	23.34	474.56K
Apr 28, 2026	23.85	24.58	22.61	24.12	498.09K
Apr 27, 2026	24.28	25.00	23.63	23.77	442.41K
Apr 23, 2026	26.53	26.73	23.78	24.31	924.45K
Apr 22, 2026	25.48	27.76	25.36	26.06	1.76M
Apr 21, 2026	25.00	25.86	24.33	25.03	1.1M
Apr 20, 2026	22.69	24.94	22.07	24.92	1.24M
Apr 17, 2026	22.02	22.70	22.00	22.54	602.78K
Apr 16, 2026	21.51	22.52	21.25	21.39	996.75K
Apr 14, 2026	20.42	21.65	20.42	21.22	602.14K
Apr 13, 2026	21.41	21.89	20.01	20.28	670.13K
Apr 10, 2026	21.40	22.02	20.54	21.57	1.07M
Apr 09, 2026	18.96	20.61	18.70	20.53	1.15M
Apr 08, 2026	19.55	19.55	18.25	19.10	817.13K
Apr 07, 2026	18.45	18.58	17.75	18.03	507.02K
Apr 06, 2026	19.06	19.40	18.61	18.61	442.76K
Apr 02, 2026	18.49	19.22	18.44	18.82	382.32K
Apr 01, 2026	18.18	18.98	18.08	18.94	597.99K

Contact Details

Princeton, NJ 08540

United States

https://www.urogen.com 646 768 9780

About Company

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization novel solutions for specialty cancers and urothelial diseases. It offers RTGel, a polymeric biocompatible and reverse thermal gelation hydrogel to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead product candidate is UGN-102, which is in Phase III clinical trials for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial carcinoma and low-grade non-muscle invasive bladder cancer. It is also developing UGN-301 for the treatment of high-grade non-muscle invasive bladder cancer. The company has a license agreement with Allergan Pharmaceuticals International Limited for developing and commercializing pharmaceutical products that contain RTGel and clostridial toxins; Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; and strategic research collaboration with MD Anderson to advance investigational treatment for high-grade bladder cancer. UroGen Pharma Ltd. was incorporated in 2004 and is based in Princeton, New Jersey.

Stock Peers

ARGX

27.59+3.52%

argenx SE$811.09 REGN

7.79+1.11%

Regeneron Pharmaceuticals, Inc.$709.21 UTHR

10.82+1.90%

United Therapeutics Corporation$581.22 MDGL

4.94002+0.96%

Madrigal Pharmaceuticals, Inc.$518.66 VRTX

5.93+1.40%

Vertex Pharmaceuticals Incorporated$429.85 PRAX

13.41+4.14%

Praxis Precision Medicines, Inc.$337.61 KRTX

0.09+0.03%

Karuna Therapeutics, Inc.$329.83 ALNY

1.815+0.61%

Alnylam Pharmaceuticals, Inc.$297.93 KRYS

20.91+7.86%

Krystal Biotech, Inc.$286.95 SGEN

-0.16-0.07%

Seagen Inc.$228.74

Company Overview

UroGen Pharma Ltd. (NASDAQ:URGN) closed at $23.29 USD, gaining $0.29 (1.26%) from the previous close of $23.00. The stock is currently mid-range between its 52-week high and low $3.42 and $30.00. With a market capitalization of about $1.13 billion, UroGen Pharma Ltd. is classified as a small-cap and shows higher-than-market volatility (beta ~1.44). Key stats such as the average daily volume over the past year has been around 795.18 thousand shares, in line with its 52-week average. Headquartered in Princeton, NJ, UroGen Pharma Ltd. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Elizabeth A. Barrett, the company employs approximately 234 people and listed since May 04, 2017. UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization novel solutions for specialty cancers and urothelial diseases.

Technical Performance

Short-term trend indicators are mixed aligned (SMA20 1.62%, SMA50 -1.01%, SMA200 16.58%). The stock’s 14-day RSI is 51.02 (neutral), while the ATR of 1.36 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -29.4% below its high and over 519.3% above its low. Average 10-day trading volume of 485.74 thousand shares is below the 3-month average of 791.06 thousand, indicating normal recent market interest.

Valuation Metrics

UroGen Pharma Ltd. trades at a P/E ratio of -7.51, slightly below the S&P 500 average, with a price-to-sales ratio of 10.38 and a price-to-book ratio of -10.93 indicating negative book value, which may reflect financial stress. The P/FCF stands at -7.0, also below market averages.

Dividend & Fair Value

UroGen Pharma Ltd. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around -$0.44. This means the shares are trading below this model’s fair value.

Earnings & Analyst Outlook

UroGen Pharma Ltd. generated EPS of -$3.46 over the past year. Five-year average earnings growth is 10.39%. The latest quarter delivered EPS of -$0.54. The next quarter is forecast at -$0.50. Next year's EPS is expected at $27.33. Analyst sentiment is bullish. Analyst rating data shows there are 3 Strong Buy ratings, 14 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $50.00 to $10.00. The high target offers 114.68% upside. The low target suggests -57.06% downside. The mean target is $31.47. This offers 35.12% upside. UroGen Pharma Ltd. earnings surprise history is a mixed track record. The quarter that ended March 02, 2026, missed forecasts by 4.25%. The prior quarter beat by -3.63%. Over the last six quarters, Apple has recorded several small beats. These include -99.93% in November 06, 2024.

Shareholding & Insider Activity

UroGen Pharma Ltd. has 46.26 million shares outstanding. The public float is 37.03 million shares, elevated short interest at 15.41% of float. This equals 7.02 million shares. The short ratio is 6.63 days. Institutional investors hold 103.22% of the float. Insiders own 3.75%. ProQuest Investments IV, L.P. holds 1.24 million shares, Barrett Elizabeth A. has 300.98 thousand shares and Schoenberg Mark has 144.98 thousand shares. Over the past six months, insider transactions show net selling. They sold 15.29 thousand shares across 3 transactions.

Financial & Profitability Overview

Over the trailing twelve months, UroGen Pharma generated $82.71M in revenue, or $2.87 per share. Gross margin was 88.68%, operating margin -79.23%, and net profit margin -123.61%. Returns are negative, with ROA at -57.34% and ROE at 156.79%.
On valuation metrics, UroGen Pharma trades at a P/E of -7.51, P/S of 10.38 and P/B of -10.93. The current ratio is 4.01 and quick ratio is 3.65. Operationally, the company’s inventory turnover is 0.76 and cash conversion cycle is 236.87 days. Debt-to-equity is -1.22, supported by a cash flow-to-debt ratio of -1.27.

Quarterly Financial Highlights

For the quarter ended Dec 31, 2023, UroGen Pharma posted revenue of $82.71M, down slightly from $64.36M in the prior quarter. Gross profit was $73.35M (margin 88.68%). Operating income was - $65.54M (margin -79.2%). Net income was- $102.24M (EPS - $3.55).
The company ended the quarter with $137.79M in cash and short-term investments, a total debt of $100.21M, and net debt of $4.39M. Total assets were $178.31M, with equity of - $65.21M. Financials further reflected weakness, with operating cash flow of - $76.38M, free cash flow of - $76.57M, and capital expenditures of - $194.00K.

Price Forecast & Outlook

Our AI price prediction model suggests that UroGen Pharma Ltd. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 13.35%, with price expected at $26.40 by May 18, 2026, within a range of $24.98 to $27.79 3-Month Outlook: Projected rise of 134.82%, reaching $54.69 by July 31, 2026, with a range of $54.01 to $55.68. 1-Year Outlook: Projected gain of 13.53%, with price at $26.44 by May 04, 2027, within a range of $25.21 to $27.94.

Key Takeaways

UroGen Pharma Ltd. (NASDAQ:URGN) shares are down -17.46% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows UroGen Pharma Ltd. trading at a premium to the broader market with a P/E of -7.51. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $38.25, suggesting 64.23% upside. Our AI forecast model points to short-term strength (13.35% over two weeks), a medium-term rise (134.82% over three months), and a longer-term gain (13.53% over one year), with expected trading ranges indicating moderate volatility.

Frequently Asked Questions

What is the current UroGen Pharma Ltd. (URGN) stock price?

UroGen Pharma Ltd. (NASDAQ: URGN) stock price is $23.29 in the last trading session. During the trading session, URGN stock reached the peak price of $23.64 while $22.69 was the lowest point it dropped to. The percentage change in URGN stock occurred in the recent session was 1.26% while the dollar amount for the price change in URGN stock was $0.29.

URGN's industry and sector of operation?

The NASDAQ listed URGN is part of Biotechnology industry that operates in the broader Healthcare sector. UroGen Pharma Ltd. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of URGN?

Mr. Jason Drew Smith
Gen. Counsel, Chief Compliance Officer & Corporation Sec.
Dr. Marina Konorty
Executive Vice President of R&D and Technical Operations
Ms. Elizabeth A. Barrett
Pres, Chief Executive Officer & Director
Mr. James Ottinger R.ph.
Executive Vice President of Regulatory Affairs & Quality
Mr. Dong Kim
Chief Financial Officer
Eric Van Zanten
Senior Director of Communications
Dr. Sari Prutchi-Sagiv Ph.D.
Marketing Director
Mr. Jeffrey Bova M.B.A.
Chief Commercial Officer
Dr. Mark P. Schoenberg M.D.
Chief Medical Officer
Vincent I. Perrone
Senior Director of Investor Relations
Mr. Eric Van Zanten
Vice President of Investor & PR

How URGN did perform over past 52-week?

URGN's closing price is 580.99% higher than its 52-week low of $3.42 where as its distance from 52-week high of $30.00 is -22.37%.

How many employees does URGN have?

Number of URGN employees currently stands at 234.

Link for URGN official website?

Official Website of URGN is: https://www.urogen.com

How do I contact URGN?

URGN could be contacted at phone 646 768 9780 and can also be accessed through its website. URGN operates from 400 Alexander Park, Princeton, NJ 08540, United States.

How many shares of URGN are traded daily?

URGN stock volume for the day was 617.48K shares. The average number of URGN shares traded daily for last 3 months was 795.18K.

What is the market cap of URGN currently?

The market value of URGN currently stands at $1.13B with its latest stock price at $23.29 and 48.68M of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

Employees	234
Beta	1.37
Sales or Revenue	$82.71M
5Y Sales Change%	39.064%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Biotechnology

URGN Company Profile and Key Details

UroGen Pharma

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Technical Performance

Valuation Metrics

Dividend & Fair Value

Earnings & Analyst Outlook

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook

Key Takeaways

Frequently Asked Questions

Technical Performance

Dividend & Fair Value

Company Overview

Earnings & Analyst Outlook

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Valuation Metrics

Price Forecast & Outlook

Key Takeaways